Recent studies have shown that approximately one-third of patients with RDD harbor mutations in genes involved in the MAPK/ERK pathway, such as NRAS, KRAS, MAP2K1, and, rarely, BRAF, indicating a neoplastic process rather than a reactive disorder [8]. This evidence concerns the gene BRAF and adjustment disorder.